• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Reducing the Risk of Comparator Sourcing

    Clinical Data Management

    Leveraging AI/ML Analytics for Better Clinical Development Decisions

    What is a Manufacturing Ecosystem and Why are They Growing?

    Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins

    RK Pharma to Receive $200M Investment from PAG

    Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease

    TMC Expands Executive Team

    Peli BioThermal Opens Cold Chain Network Station in Southern California
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins

    RK Pharma to Receive $200M Investment from PAG

    Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease

    Peli BioThermal Opens Cold Chain Network Station in Southern California

    Purolite Expands Bioprocessing Production Capacity with New U.S. Facility
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Peli BioThermal Opens Cold Chain Network Station in Southern California

    Biocair Partners with TrakCel to Improve Visibility in the Supply Chain

    SpectronRx, RLS Partner to Boost Radiopharmaceutical Pipeline and Supply Chain

    Serialization and the War on Counterfeit Drugs

    Traceability & 2D Barcodes
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    RK Pharma to Receive $200M Investment from PAG

    Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease

    Almac Group Global Workforce Hits 7,000 Employees

    Amarna Therapeutics Names Henk Streefkerk CEO

    Trinity Life Sciences Names Leslie Orne CEO
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Regulatory Affairs: Accelerating Drug Development Timelines

    Berkshire Sterile Secures Over $230,000 in Training Grants

    Purification – A Bottleneck for Large-Scale Manufacturing of Oligonucleotide API?

    FDA 2023 Inspection Roadmap: Is “Readiness” in Your Annual Objectives?

    FDA Watch: Are You Suitably Staffed?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    CMC Pharmaceuticals

    INCOG BioPharma Services

    LOTTE BIOLOGICS

    Societal CDMO

    Almac Group
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    CMC Pharmaceuticals

    INCOG BioPharma Services

    LOTTE BIOLOGICS

    Societal CDMO

    Almac Group
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    The Importance of Humanizing FTEs in Drug Discovery

    The evolution of the FTE model and the different ways it can be utilized.

    The Importance of Humanizing FTEs in Drug Discovery
    Paul Overton, Chief Commercial Officer, Sygnature Discovery05.03.23
    In recent years, there has been a growing reliance on outsourcing as a key pillar in the research and development of new pharmaceuticals. Indeed, outsourcing strategies have matured, taking learnings from other industrial sectors to maximize the value that these service provider relationships provide. Professional procurement experts, working in synergy with the scientists, now routinely focus on the value of the supply chain, supplier segmentation, and the three core building blocks of supplier management: price, quality, and delivery.1

    Outsourcing maturity and industry consolidation around simplifying the value chain to increase customer value and reduce cost have driven huge changes in the CMC, clinical, regulatory preclinical, and discovery space. One critical piece of outsourcing strategy is the “unitization” and “standardization” of services to allow direct comparison of providers services.

    Within the discovery, CMC and analytical space, the term FTE (Full Time Equivalent) has become almost a universal to support R&D service-related activities. Either directly or as a price build up, the FTE has become the standard unit of measurement.

    Questions that often arise early on in commercial discussions are around how much an FTE costs; how many hours per week they actively deliver; how many activities each can carry out per week; how many years of experience they have, etc.—seemingly standardizing or commoditizing the expertise of the scientists involved.

    It conjures up images of rows of identical scientific robots in a warehouse (aka the movie I-Robot) just waiting to be utilized in each contract.

    But fortunately, most scientists are not faceless robots; they vary greatly in their experience, expertise, team interactivity and communication skills—and therefore, also in the value they can bring to a drug discovery project. To make the most of outsourcing, the focus should be less on the top line cost per FTE, and more on the value those FTEs create on the project for you.

    Defining FTE value

    Just focusing on cost-per-FTE tips the cost-value equation in the wrong direction and underplays the potential value creation opportunity for the pharma or biotech company. According to value experts Neil Rackham, Malcolm MacDonald, Philip Kotler2 and others, there is a simple definition of value: Value equals benefits minus cost—V=B-C.

    If you follow the logic of that equation, then value creation must focus on the benefits rather than the basic costs.

    However, many commercial conversations around FTE rates inevitably focus on the delivery from the given scientist or team of scientists. Classic procurement scorecards and metrics typically focus on aspects such as the number and speed of DMT (Design, Make, Test) cycles; number of reactions performed and compounds created; the number of samples screened; batches performed; failure rates, etc. These are all useful ways to assess the performance of given activities and to discuss when things do not go to plan, but there is another way.

    Models utilizing FTEs

    Taking a step back and looking at the different ways an FTE team can be utilized can help you to make the most appropriate decision. There are potentially several options, depending largely on IP considerations and your internal resourcing needs:

    1. Fully directed FTE
    In this type of agreement, a dedicated team of FTE scientists who are typically discipline focussed (in vitro, DMPK, pharmacology, etc.) are given clear, regular instructions on methods or protocols to follow.

    With this approach, effectively all the intellectual value remains with the pharma or biotech company. The FTE team adds little to no scientific value or innovation to the project other than offering capable “pairs of hands” to perform the allocated task, for instance, making some specified molecules or screening compounds, as requested.

    This approach requires strong customer project management, strong data interpretation, and good communication to ensure the instructions are followed correctly. Effectively, it doesn’t matter where those pairs of hands are located, whether it’s Europe, the U.S. or Asia.

    This FTE model, however, fails to utilize the potential expertise of the team, and can often cost more than initially budgeted. The FTE “cost” may initially be attractively low, but the TCS (Total Cost of Service) may be significantly higher when active management time and support costs such as re-chargeables, travel and shipping are all wrapped in.

    2. FTEs as part of your research team
    With this approach, the FTEs are not just pairs of hands performing activities; they also act as a key part of your research team, directly inputting their expertise and knowledge. They provide intellectual input and innovation into the delivery of the project.

    While the scorecards and metrics are still key to managing the housekeeping of the project, there would typically be a scientific team leader providing updates and data interpretation of the recent work performed.

    Using this model, the FTE robots are effectively becoming humanized.

    3. Multi-disciplinary FTE teams
    In this agreement, the FTE team is a multi-disciplinary group with an internal project lead, and typically clear joint governance, that acts and performs as part of your own team. They impart ideas into the wider team, and their proximity to each other sparks innovation and new ways of thinking.

    This “group ideas” thinking is sometimes called serendipity knowledge exchange, but in practice, it creates value beyond just the individual. The focus on a team approach with real intellectual input moves us away from the classic metrics and scorecards, and towards a model based upon joint aims and milestones. And ultimately, hopefully, towards molecules that show efficacy, good safety, and appropriate DMPK profiles.

    Members of the multi-disciplinary team can also potentially be independent advisors that can highlight and advise on project termination if the science does not support the overall project aims.
    In this case, the FTE robots have become partners in the project—they are invested.

    Creating genuine value

    Having spent time on both sides of this equation, I am a firm believer that all FTEs are not created equal. As with any relationship, you need to look at value creation—not just cost.
    As MacDevitt and Wilkinson3 highlight, value can be thought of as a triad:

    • Revenue gains (asset success)
    • Cost reductions (total cost of ownership)
    • Emotional contribution (feel good factor)

    All these factors are important to consider when choosing to outsource to an external partner.

    There is a real difference between a unitized, commoditized service and an innovative partner-type arrangement. What value will it add beyond simply the discipline services you buy? Will the FTE become, essentially, part of the team, working to push the project forward in a more substantial way than simply making molecules?

    Extending the partnership into a multi-disciplinary arrangement can add even more value, with biologists and analytical scientists all working together to create it. The total cost–value proposition of such a partnership will be more difficult to quantify, of course. It goes beyond simple KPIs and metrics, which typically omit the value created by the outsourced team’s expertise.

    Final thoughts

    A hundred chemicals delivered may tick a lot of KPI boxes for an outsourcing contract, but if they are all poor quality, they simply represent a lot of wasted effort. You would be far better off if the project only delivered a handful of molecules with drug-like properties. And engaging FTEs who are experienced drug-hunters—not just good synthetic chemists—will make this far more likely.

    References
    1. Category Management in Purchasing Jonathan O’ Brian Kogan-Page 2012
    2. Lynette Ryals Managing Customers Profitably Wiley Publications 2008
    3. Harry MacDivitt & Mike Wilkinson: Value Based Pricing 2012 McGaw Hill ISBN 978 0 07 176168 0



    Dr. Paul Overton is Chief Commercial Officer at Sygnature Discovery and has over 20 years of commercial experience in the pharmaceutical and biotechnology sectors, delivering integrated discovery and development solutions. After initially working in the research developing diagnostics and cell biology services, he transitioned into a commercial career in the non-clinical development space.
    Related Searches
    • R&D
    • Drug Discovery
      Loading, Please Wait..
      Trending
      • SpectronRx, RLS Partner To Boost Radiopharmaceutical Pipeline And Supply Chain
      • Samsung Biologics Accelerates Timeline Of New Fifth Plant
      • Biopharma Layoffs In 1Q23
      • Veeva Business Consulting Expands With New R&D Services
      • CRO Industry Trends & Challenges
      Breaking News
      • EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins
      • RK Pharma to Receive $200M Investment from PAG
      • Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease
      • TMC Expands Executive Team
      • Peli BioThermal Opens Cold Chain Network Station in Southern California
      View Breaking News >
      CURRENT ISSUE

      May 2023

      • New Modalities Hog the Limelight
      • Cell and Gene Therapy is Coming of Age
      • Demand Surges for Cell and Gene Therapy Contract Manufacturing
      • Embracing a New Reality
      • Japan: A Unique Opportunity for Regenerative Medicines and Cell & Gene Therapies
      • Single-Use Technologies Enable Biologic Scaling
      • Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
      • FTEs in Drug Discovery
      • Digital Transformation in Pharma
      • What is a Manufacturing Ecosystem and Why are They Growing?
      • View More >

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Sempera Organics and Alkemist Labs Announce Partnership for Mushroom Testing
      Nektium Expands International Distribution Network for Botanical Extracts
      Kemin Receives Positive EFSA Opinion for BetaVia Pure, its Beta-Glucan Ingredient
      Coatings World

      Latest Breaking News From Coatings World

      PPG’s New Paint for a New Start Initiative to Beautify Schools Worldwide with Colorful Makeovers
      Powder Technology, Inc. Announces New Electrical Coating
      Michelman Chosen as Inaugural Recipient of Innovation Research Interchange (IRI) Excellence Award
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Cue Health Nabs FDA's First De Novo Nod for an At-Home COVID Test
      ISO 13485:2016 Certification Granted to Boston BioProducts
      Paul Colvin Joins Ora Inc. as Chief Operating Officer
      Contract Pharma

      Latest Breaking News From Contract Pharma

      EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins
      RK Pharma to Receive $200M Investment from PAG
      Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Estée Lauder Announces Second Edition of Beauty&You Brand Incubator Program
      GetHarley Raises $52 Million in Latest Funding Round
      Refillable Skincare Products Face Hurdles Despite Growing Sustainability Awareness
      Happi

      Latest Breaking News From Happi

      Carrière Frères Introduces Candle Refills as New Sustainability Initiative
      Gen Z Entrepreneur Introduces The Ashley Marie Collection for 4C Hair Types
      The Estée Lauder Companies Expands Beauty&You Competition for Indian Beauty Brands
      Ink World

      Latest Breaking News From Ink World

      Siegwerk’s Center of Excellence in France Receives Facelift
      Epson announces MakeTheSwitch Campaign
      Pigments Market to Reach $26,598 Million by 2022: AMR
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Mark Andy reports successful Low Migration Workshop
      Ryback and Ryback Consulting launches Machinery division
      TLMI launches 2023 award programs
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      The Honest Company to Exit Europe, Asia
      TechnoPlants to Exhibit at ITMA
      Andritz Buys 100% Stake in Dan-Web
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Orthobiologics Market to Top $10.3 Billion by 2030
      Artelon Granted U.S. FDA 510(k) Clearance for FlexBand, FlexPatch & FlexBand Plus
      Synergy Spine Solutions Completes Enrollment in IDE Clinical Trial
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      ASSA ABLOY Receives Clearance from Mexico for HHI Acquisition
      Christoph Ostermann Named Chairman of Heliatek‘s Advisory Board
      Flexible and Printed Electronics Represented at productronica 2023

      Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login